is-elestrin-right-for-you
 
 

A study of Elestrin demonstrated that it provides significant reductions in both the frequency and severity of moderate-to-severe hot flashes and night sweats.

The women in the Elestrin study were experiencing an average of 13 hot flashes per day when they entered the study.1,2 The average severity score for the women in the study at the beginning was 2.4 on a 4-point scale, where 3 = Severe.1,2

Elestrin significantly reduced the number of hot flashes.

The average number of hot flashes among the group had been significantly reduced by week 3 using the 2-pump dose, and by week 5 using the 1-pump dose.1

Elestrin significantly reduced the severity of hot flashes.

The severity of hot flashes was also significantly reduced by Week 4 using the 2-pump dose, and by Week 5 using the 1-pump dose.1,2

It’s simple for your doctor to adjust your dose depending on how severe your symptoms are.

Elestrin delivers a metered dose—the same amount with each pump.

If your hot flashes are more severe, your doctor may start you on the two-pump dose to help get your symptoms under control. Your doctor may then adjust your dose, depending on how your respond to Elestrin therapy.

References:

1.    Simon JA, Bouchard C, Waldbaum A, et al. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007;109:588-596.

2.    Elestrin™ [package insert]. San Antonio TX: Kenwood Therapeutics, 2007.

 
 

Important Safety InformationElestrin is indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.

Estrogens, with or without progestins, should not be used for the prevention of cardiovascular disease or dementia. Estrogen and progestin therapy has shown an increased risk of breast cancer, heart attack, and blood clots. Estrogen therapy, with or without progestins, increases the risk of stroke and dementia. Estrogen therapy alone increases the risk of endometrial cancer. The most frequently reported adverse events in clinical trials were nasopharyngitis, breast tenderness, upper respiratory tract infection, and metrorrhagia.

Please see Full Prescribing Information, including Black Box Warning

 
 

Close (x)

A Survey of 300 untreated menopausal women reveal what they want from the application of transdermal estrogen therapy†:

"I want a product I can apply and forget it."

"I’d rather just rub the product in and forget it’s there."

"For me, it’s easier to get into a daily habit."

"I like the control of applying [it] right on my upper arm."

"Make it clear and easy to apply."

†A blinded survey of 300 women with hot flashes to evaluate the importance of various attributes of transdermal estrogen therapy and the preference for various topical estrogen therapy products. Azur Pharma; 2009.